Movatterモバイル変換


[0]ホーム

URL:


GB0525083D0 - Pyrimidine derivatives - Google Patents

Pyrimidine derivatives

Info

Publication number
GB0525083D0
GB0525083D0GBGB0525083.2AGB0525083AGB0525083D0GB 0525083 D0GB0525083 D0GB 0525083D0GB 0525083 AGB0525083 AGB 0525083AGB 0525083 D0GB0525083 D0GB 0525083D0
Authority
GB
United Kingdom
Prior art keywords
pyrimidine derivatives
pyrimidine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB0525083.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca ABfiledCriticalAstraZeneca AB
Priority to GBGB0525083.2ApriorityCriticalpatent/GB0525083D0/en
Publication of GB0525083D0publicationCriticalpatent/GB0525083D0/en
Priority to PCT/GB2006/004553prioritypatent/WO2007066102A1/en
Pendinglegal-statusCriticalCurrent

Links

Classifications

Landscapes

GBGB0525083.2A2005-12-092005-12-09Pyrimidine derivativesPendingGB0525083D0 (en)

Priority Applications (2)

Application NumberPriority DateFiling DateTitle
GBGB0525083.2AGB0525083D0 (en)2005-12-092005-12-09Pyrimidine derivatives
PCT/GB2006/004553WO2007066102A1 (en)2005-12-092006-12-06Pyrimidine derivatives

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
GBGB0525083.2AGB0525083D0 (en)2005-12-092005-12-09Pyrimidine derivatives

Publications (1)

Publication NumberPublication Date
GB0525083D0true GB0525083D0 (en)2006-01-18

Family

ID=35735812

Family Applications (1)

Application NumberTitlePriority DateFiling Date
GBGB0525083.2APendingGB0525083D0 (en)2005-12-092005-12-09Pyrimidine derivatives

Country Status (2)

CountryLink
GB (1)GB0525083D0 (en)
WO (1)WO2007066102A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
MX2009002046A (en)2006-08-242009-03-06Astrazeneca AbMorpholino pyrimidine derivatives useful in the treatment of proliferative disorders.
BRPI0814503A2 (en)*2007-07-092017-05-16Astrazeneca Ab compound, use of a compound, methods for producing an antiproliferative effect in a warm-blooded animal, and for treating a disease, and, pharmaceutical composition
KR20100042280A (en)*2007-07-092010-04-23아스트라제네카 아베Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k
US20100311776A1 (en)*2008-01-302010-12-09Smithkline Beecham CorporationNovel sEH Inhibitors and their Use
EP2240021A4 (en)*2008-01-302011-08-17Glaxosmithkline LlcNovel seh inhibitors and their use
EP2240025A4 (en)*2008-01-302012-03-28Glaxosmithkline LlcNOVEL sEH INHIBITORS AND THEIR USE
TW200948362A (en)*2008-04-092009-12-01Mitsubishi Tanabe Pharma CorpNew compounds and their uses
GB0818241D0 (en)*2008-10-062008-11-12Cancer Res TechnologyCompounds and their use
CA2755554C (en)*2009-04-172013-09-24Wyeth LlcPyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
UA110697C2 (en)2010-02-032016-02-10Сігнал Фармасьютікалз, Елелсі USE OF TOR KINASE INHIBITORS FOR TREATMENT OF TUMOR DISEASES IN A PATIENT WITH A REDUCED PAMPK PROTEIN AND / OR AMPK ACTIVITY
SA111320519B1 (en)2010-06-112014-07-02Astrazeneca Ab Pyrimidinyl compounds for use as ATR inhibitors
MX2014001246A (en)2011-08-032014-06-11Signal Pharm LlcIdentification of gene expression profile as a predictive biomarker for lkb1 status.
WO2013041457A1 (en)*2011-09-222013-03-28Msd Oss B.V.N-piperidin-4-yl derivatives
AU2013203714B2 (en)2012-10-182015-12-03Signal Pharmaceuticals, LlcInhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
KR102242505B1 (en)2013-04-172021-04-20시그날 파마소티칼 엘엘씨Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
BR112015026238A8 (en)2013-04-172019-12-24Signal Pharm Llc dihydropyrazino-pyrazine compound, pharmaceutical composition comprising it, use of the compound, methods to inhibit or measure phosphorylation and to inhibit protein kinase activity, as well as a kit
UA115805C2 (en)2013-04-172017-12-26Сігнал Фармасьютікалз, ЕлелсіCombination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
KR20160004273A (en)2013-04-172016-01-12시그날 파마소티칼 엘엘씨PHARMACEUTICAL FORMULATIONS, PROCESSES, SOLID FORMS AND METHODS OF USE RELATING TO 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL)PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO[2,3-b]PYRAZIN-2(1H)-ONE
KR102240356B1 (en)2013-04-172021-04-14시그날 파마소티칼 엘엘씨Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
WO2014172426A1 (en)2013-04-172014-10-23Signal Pharmaceuticals, LlcTreatment of cancer with dihydropyrazino-pyrazines
KR20160002792A (en)2013-04-172016-01-08시그날 파마소티칼 엘엘씨Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethyoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
CN109503591B (en)2013-05-292022-03-01西格诺药品有限公司Pharmaceutical compositions of dihydropyrazinopyrazine compounds, solid forms thereof and their use
WO2015160880A1 (en)2014-04-162015-10-22Signal Pharmaceuticals, LlcSOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en)2014-04-162017-04-28Signal Pharm LlcSolid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
KR102496364B1 (en)*2014-09-102023-02-06에피자임, 인코포레이티드Smyd inhibitors
CN110996955A (en)2017-06-222020-04-10细胞基因公司 Treatment of hepatocellular carcinoma characterized by hepatitis B virus infection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
ES2375111T3 (en)*2002-11-212012-02-24Novartis Ag PYRIMIDINES 2,4,6-TRISUSTITUIDAS AS INHIBITORS OF FOSFOTIDILINOSITOL (PI) 3-QUINASA AND ITS USE IN THE TREATMENT OF C�? NCER.
GB0415365D0 (en)*2004-07-092004-08-11Astrazeneca AbPyrimidine derivatives
GB0415364D0 (en)*2004-07-092004-08-11Astrazeneca AbPyrimidine derivatives

Also Published As

Publication numberPublication date
WO2007066102A1 (en)2007-06-14

Similar Documents

PublicationPublication DateTitle
AP2008004486A0 (en)Pyrimidine derivatives
IL181433A0 (en)Pyrimidine derivatives
IL192610A0 (en)Pyrimidine derivatives
IL181386A0 (en)Pyrimidine derivatives
GB0415364D0 (en)Pyrimidine derivatives
GB0525080D0 (en)Pyrimidine derivatives
GB0614579D0 (en)Pyrimidine derivatives
EP1878727A4 (en)2-aminoquinazoline derivatives
HUS2000022I1 (en)Tiglien-3-one derivatives
IL185674A0 (en)1-benzylindole-2-carboxamide derivatives
IL179914A0 (en)Pyrimidine derivatives
ZA200805411B (en)Aryl-isoxazolo-4-yl-oxadiazole derivatives
PH12012501003A1 (en)Oxygen linked pyrimidine derivatives
GB0525083D0 (en)Pyrimidine derivatives
PL1954674T3 (en)New n-phenethylcarboxamide derivatives
ZA200802088B (en)4-Phenyl-6-substitued-pyrimidine-2-carbonitrile derivatives
ZA200802421B (en)1-Acyldihydropyrazol derivatives
ZA200804257B (en)Azaindole-2-carboxamide derivatives
IL184841A0 (en)Substituted aminoalkyl-and amidoalkyl-benzopyran derivatives
IL192235A0 (en)Aryl-isoxazol-4-yl-imidazole derivatives
GB0415367D0 (en)Pyrimidine derivatives
EP2094704A4 (en)Cis-cyclohexyl substituted pyrimidinone derivatives
GB0525081D0 (en)Pyrimidine derivatives
IL191138A0 (en)Pyrazoloisoquinoline derivatives
GB0504018D0 (en)Quinazoline derivatives

[8]ページ先頭

©2009-2025 Movatter.jp